Figure 1.
Figure 1. Effect of rhIL-11 and DDAVP on VWF:Ag levels in heterozygous VWD and normal dogs. One heterozygous VWD dog C107 (open squares) and 2 normal dogs, C80 and C81 (filled squares, average value labeled) were treated daily for 7 days with either rhIL-11 (panel A, 50 μg/kg subcutaneously; white bar), or DDAVP (panel B, 5 μg/kg intravenously; black bar). Results are shown for pretreatment; for 30-minute and 4-hour samples for each of the 7 treatment days; and for the subsequent 7 days after treatment. C80 and C107 developed estrus on day 2 of rhIL-11 therapy.

Effect of rhIL-11 and DDAVP on VWF:Ag levels in heterozygous VWD and normal dogs. One heterozygous VWD dog C107 (open squares) and 2 normal dogs, C80 and C81 (filled squares, average value labeled) were treated daily for 7 days with either rhIL-11 (panel A, 50 μg/kg subcutaneously; white bar), or DDAVP (panel B, 5 μg/kg intravenously; black bar). Results are shown for pretreatment; for 30-minute and 4-hour samples for each of the 7 treatment days; and for the subsequent 7 days after treatment. C80 and C107 developed estrus on day 2 of rhIL-11 therapy.

Close Modal

or Create an Account

Close Modal
Close Modal